mAbxience, a developer and manufacturer of biopharmaceutical products, and part of the Fresenius Kabi and Insud Pharma groups, has entered an agreement with Biosidus, an Argentine company specialized in biotechnology, focused in the area of CDMO (Contract Development and Manufacturing Organization).   Under the agreement, mAbxience will be responsible for the manufacture of the active ingredient Agalsidase Beta, developed by Biosidus as a biosimilar of Fabrazyme. An Innovative Treatment fo...